Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug;25(8):857-867.
doi: 10.1007/s11912-023-01422-4. Epub 2023 May 2.

Intratumoral Immunotherapy: Is It Ready for Prime Time?

Mario Ghosn  1   2 , Lambros Tselikas  3   4   5   6 , Stéphane Champiat  2   7   8 , Frederic Deschamps  1 , Baptiste Bonnet  1 , Émilie Carre  2 , Marine Testan  2 , François-Xavier Danlos  2   7   8 , Siham Farhane  2 , Sandrine Susini  2   7 , Steve Suzzoni  9 , Samy Ammari  10   11 , Aurélien Marabelle  2   7   12   8 , Thierry De Baere  1   2   12
Affiliations
Review

Intratumoral Immunotherapy: Is It Ready for Prime Time?

Mario Ghosn et al. Curr Oncol Rep. 2023 Aug.

Abstract

Purpose of review: This review presents the rationale for intratumoral immunotherapy, technical considerations and safety. Clinical results from the latest trials are provided and discussed.

Recent findings: Intratumoral immunotherapy is feasible and safe in a wide range of cancer histologies and locations, including lung and liver. Studies mainly focused on multi-metastatic patients, with some positive trials such as T-VEC in melanoma, but evidence of clinical benefit is still lacking. Recent results showed improved outcomes in patients with a low tumor burden. Intratumoral immunotherapy can lower systemic toxicities and boost local and systemic immune responses. Several studies have proven the feasibility, repeatability, and safety of this approach, with some promising results in clinical trials. The clinical benefit might be improved in patients with a low tumor burden. Future clinical trials should focus on adequate timing of treatment delivery during the course of the disease, particularly in the neoadjuvant setting.

Keywords: Immunotherapy; Interventional radiology; Intratumoral; Oncology.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535–46. - PubMed - DOI
    1. Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim S-W, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381:2020–31. - PubMed - DOI
    1. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905. - PubMed - DOI
    1. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–68. - PubMed - DOI
    1. Verma V, Sprave T, Haque W, Simone CB, Chang JY, Welsh JW, et al. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer. 2018;6:128. - PubMed - PMC - DOI

Publication types

LinkOut - more resources